

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



09/202035
PC/AU/97/00351

REC'D 24 JUN 1997

WIPO PCT

Patent Office
Canberra

I, DAVID DANIEL CLARKE, ASSISTANT DIRECTOR PATENT SERVICES, hereby certify that the annexed are true copies of the Provisional specification and drawing(s) as filed on 5 June 1996 in connection with Application No. PO 0265 for a patent by BIOMOLECULAR RESEARCH INSTITUTE LTD filed on 5 June 1996.

I further certify that the annexed documents are not, as yet, open to public inspection.

PRIORITY DOCUMENT



WITNESS my hand this Twelfth
day of June 1997

DAVID DANIEL CLARKE
ASSISTANT DIRECTOR PATENT SERVICES

380505186

AUSTRALIAN	
PROVISIONAL NO.	DATE OF FILING
P00265	-5 JUN. 96
PATENT OFFICE	

AUSTRALIA

Patents Act 1990

PROVISIONAL SPECIFICATION

Applicant(s): BIOMOLECULAR RESEARCH INSTITUTE LTD

A.C.N. 050 135 012

Invention Title: VIRAL PEPTIDE

The invention is described in the following statement:

VIRAL PEPTIDE

This invention relates to viruses of the family Paramyxoviridae, particularly viruses of the respiratory syncytial virus group. More particularly, the invention relates to attachment protein of these viruses, and to the structure of the region of the attachment protein which is involved with binding to the cellular receptor for the virus.

Background of the Invention

Respiratory syncytial viruses are significant pathogens of human and animals throughout the world. Virtually all humans become infected with human respiratory syncytial virus (RSV) by two years of age, and repeated infections occur throughout life. RSV is regarded as the most serious respiratory pathogen of infants and young children, but it can also cause serious disease in immunocompromised adults and in the elderly. Serious cases of infection manifest in bronchiolitis and pneumonia, and can be fatal. Estimates of the impact of RSV infection indicate that it results in 91,000 hospital admissions annually in the United States of America (Heilman, 1990) and hospitalisation of 1% of children before the age of 12 months in Britain (Cane and Pringle, 1995). Epidemics of the virus occur on an annual basis coincidental with other viruses, such as influenza and parainfluenza.

Natural immunity does not appear to provide protection against RSV infection (McIntosh and Chanock, 1990; Hall, 1994). Even infants provided with maternal antibodies are susceptible to RSV infection (McIntosh, 1990). Vaccine development strategies to combat RSV have not been successful, and in one study a formalin-inactivated virus vaccine actually exacerbated disease (McIntosh and Chanock, 1990; Hall, 1994). The only pharmaceutical agent presently available to treat RSV,

Ribavirin, is expensive and complex to deliver as an aerosol, and is of questionable efficacy (McIntosh, 1990; Levin, 1994). Thus it is apparent that a greater understanding of the infectious mechanism and immunobiology of RSV is required to develop control measures based on vaccines or antiviral agents.

RSV belongs to the *Pneumovirus* genus of the Paramyxoviridae family of single strand negative sense RNA viruses, which includes other serious pathogens such as parainfluenza, mumps and measles (McIntosh, 1990; Kingsbury, 1990) and the recently identified zoonotic, equine morbillivirus (Murray et al, 1995). Like other Paramyxoviridae, RSV has two membrane glycoproteins which mediate invasion of susceptible cells (Morrison and Portner, 1991). One protein, the large glycoprotein or G protein, functions in attachment to cells. The other, the so-called fusion or F protein, causes fusion between the lipid of the viral membrane envelope and the cell plasma membrane lipid bilayer. RSV infection can also be transmitted by fusion of membranes of infected cells, which have F protein expressed on their surface, with adjacent cells.

The molecular architecture of the F protein is conserved between all members of the three genera of the Paramyxoviridae; however, each genus has a characteristic attachment protein (Morrison and Portner, 1991). Members of the *Paramyxovirus* genus have attachment proteins with neuraminidase and haemagglutinating activities; the attachment proteins of the *Morbillivirus* genus are haemagglutinins, but lack neuraminidase activity; and the attachment proteins of *Pneumoviruses* lack both haemagglutination and neuraminidase properties. Attachment proteins of the *Paramyxovirus* (Morrison and Portner, 1991) and *Morbillivirus* (Dore-Duffy and Howe, 1978) genera participate in sialic acid receptor-type interactions, which account for their ability to agglutinate red blood

cells. RSV is also reported to interact with sialic acid; however, the mechanism of RSV G protein attachment and the identity of the cellular receptor for the G protein are not yet known (Markwell, 1991).

5 The Paramyxoviridae F protein is invariably a
type I integral membrane protein, but the attachment
proteins are all type II integral membrane proteins. The
oligosaccharide compositions of the *Paramyxovirus* and
10 *Morbillivirus* attachment proteins are typical of integral
membrane proteins (Morrison and Portner, 1991), but the RSV
attachment protein, also termed the G protein, appears to
contain an unusually high proportion of carbohydrate
(Morrison and Portner, 1991; reviewed by Sullender and
Wertz, 1991). The gene for the RSV strain A2 attachment
15 protein encodes a potential primary translation product of
298 amino acids with a theoretical Mr of 32588 (Satake et
al, 1985; Wertz et al, 1985), but has an apparent molecular
weight of 80,000-90,000 (Levine, 1977; Gruber and Levine,
1983; Lambert and Pons, 1983) as estimated by
20 electrophoresis in polyacrylamide gels containing sodium
dodecylsulfate (SDS-PAGE). The unusually high molecular
weight of the RSV attachment protein as measured by
SDS-PAGE has been attributed to a high content of both O-
and N-linked oligosaccharides (Gruber and Levine, 1985;
25 Lambert, 1988).

It has been suggested that the conserved region
in the central part of the G protein ectodomain may be
involved in ligand interactions with a cellular receptor
for the G protein (Collins, 1991; Johnson et al, 1987);
30 however, this remains to be demonstrated. Peptide epitope
scanning experiments, using nested sets of synthetic
peptides, have identified the cysteine-containing region as
a subtype-specific antigenic determinant (Norrby et al,
1987) which shows some dependence on oxidation of the
35 cysteines to cystine (Akerlind-Stopner et al, 1990).
Monoclonal antibodies which react with this region also

block binding of the G protein to cells (Feldman and Hendry, 1996). However, the disulphide linkage status of this region remains to be elucidated. In addition, the glycosylation status of the serine and threonine residues in the conserved domain and around the conserved cysteine residues or the Asn-Pro-Thr sequence between cysteines 176 and 182 of the ectodomain has not been determined, and the sites of disulphide bonds are not known.

We have now found that the four cysteine residues of the ectodomain form a uniform disulphide bond pattern, and that the region of the protein around these residues and the conserved region lack oligosaccharide attachment. This finding has significance for the design and production of vaccines, diagnostic reagents, and therapeutic compounds for human RSV and related viruses.

In particular, the absence of glycosylation leaves this region of the ectodomain open for receptor binding. Heretofore, the possibility of attached oligosaccharide being present in this region has meant that the design and interpretation of experiments to examine binding of the virus to its cellular receptor has been exceedingly difficult, and accurate interpretation almost impossible, because of the level of variability made possible by glycosylation.

Summary of the Invention

According to one aspect, the invention provides a compound having structural homology to a contiguous sequence of amino acids within the sequence representing residues 149-197 of the G protein of respiratory syncytial virus, in which

- a) no oligosaccharide is linked to potential serine, threonine or asparagine attachment sites;
- b) four cysteine residues are involved in disulphide linkages; and

c) the pattern of disulphide linkage is Cys 173 linked to Cys 186, and Cys 176 linked to Cys 182, and in which said compound possesses a biological activity of respiratory syncytial virus G protein.

5 For the purposes of this specification, a biological activity of respiratory syncytial virus G protein is defined as one or more of

a) the ability to bind to one or more antibodies selected from the group consisting of rabbit polyclonal antibody directed against RSV, murine monoclonal antibody directed against RSV, and antibodies present in human convalescent sera from patients infected with RSV; and

15 b) the ability to bind to cells capable of being infected with RSV.

Preferably the virus is selected from the group consisting of human RSV subtype A, human RSV subtype B, bovine RSV, and mutants and variants thereof.

20 More preferably the compound is a peptide corresponding to amino acids 158 to 196 of the RSV G protein. Even more preferably the peptide corresponds to amino acids 165 to 187 of the RSV G protein.

Most preferably the compound is a peptide having one of the following amino acid sequences:

25	SEQ ID NO 1	KQRQNKPPSKPNNDHFHFEVFNFPVPCISICSNNPTCWAICKRIPNKKPGKK
	SEQ ID NO 2	-----N-----
	SEQ ID NO 3	-----R
	SEQ ID NO 4	--H-----
	SEQ ID NO 5	-----N-----
30	SEQ ID NO 6	-----N-----
	SEQ ID NO 7	-----N-----
	SEQ ID NO 8	-----R
	SEQ ID NO 9	-S-SKN--K--KD-Y-----G--QL-KS--T--SN--K--
	SEQ ID NO 10	-S-SKN--K--KD-Y-----G--QL-KS--T--SN--K--
35	SEQ ID NO 11	-P-PKN--K--KD-Y-----G--QL-KS--T--SN--K--
	SEQ ID NO 12	-P-LKN--K--KD-Y-----G--QL-KS--T--SN--K--
	SEQ ID NO 13	-P-LKN--K--KD-Y-----G--QL-KS--T-SSN--K--

SEQ ID NO 14 -P-LKN--K--KD-Y-----G--QL-KS---T--SN--K--
SEQ ID NO 15 -S-SKN--K--KD-Y-----G--QL-KS---T--SN--K--
SEQ ID NO 16 NPSGSI--ENHQDHNN-QTLPY----T-EG-LA-LSL-HIETERA-SRA
SEQ ID NO 17 -----P-----T-----R-----
5 SEQ ID NO 18 -----S-----R--T-----

Sequences encompassing conservative substitutions of amino acids are within the scope of the invention, provided that the biological activity is retained.

It is to be clearly understood that the compounds of the invention include peptide analogues, including but not limited to the following:

1. Compounds in which one or more amino acids is replaced by its corresponding D-analogue. The skilled person will be aware that retro-inverso amino acid sequences can be synthesised by standard methods; see for example Choreo and Goodman, 1993;

2. Peptidomimetic compounds, in which the peptide bond is replaced by a structure more resistant to metabolic degradation. See for example Olson et al, 1993; and

3. Compounds in which individual amino acids are replaced by analogous structures for example, gem-diaminoalkyl groups or alkylmalonyl groups, with or without modified termini or alkyl, acyl or amine substitutions to modify their charge.

The use of such alternative structures can provide significantly longer half-life in the body, since they are more resistant to breakdown under physiological conditions.

Because of the biological activity of the compounds of the invention, they are useful as therapeutic and diagnostic agents, and are also useful in the screening in order to identify compounds capable of inhibiting binding of the virus to its host cell. Therefore the invention also provides

a) a diagnostic composition comprising a compound of the invention;

b) a pharmaceutical composition comprising a compound of the invention together with a pharmaceutically acceptable carrier;

c) a method of prevention or treatment of *Pneumovirus* infection comprising the step of administering an effective amount of a compound of the invention to a mammal in need of such treatment; and

d) a method of diagnosis of *Pneumovirus* infection, comprising exposing a biological fluid or sample from a mammal suspected of being infected with said virus to a compound of the invention, and measuring the interaction between the compound and said fluid or sample.

Diagnostic kits are also within the scope of the invention.

Because at least some compounds of the invention are immunogenic, in a further aspect the invention provides a method of immunisation against *Pneumovirus* infection, comprising the step of immunising a mammal at risk of such infection with an immunising-effective dose of a compound of the invention, said compound being immunogenic and having the ability to elicit protective antibody.

Similarly, even where the antibodies produced in response to immunisation with a compound of the invention are not protective, such antibodies will be useful as diagnostic reagents. For this application of the invention the only requirement is that the antibodies elicited have the capacity to interact with a *Pneumovirus* in a detectable manner. For example, the antibody can be coupled to a detectable marker such as a radioactive label, a fluorescent marker, a luminescent marker or an enzyme marker. The person skilled in the art will be aware of a great variety of suitable such markers. Thus both non-protective and protective antibodies directed against compounds of the invention are also within the scope of the

invention.

Compounds according to the invention may be directly labelled with a detectable marker; such as those mentioned above for labelling of antibodies, and/or with a photoaffinity label, and are useful for identification and structural characterization of the cellular receptor for RSV and other Pneumoviruses. Knowledge of the structure of the receptor and the mechanism of its interaction with the G protein is useful in the design of antiviral compounds.

The person skilled in the art will be aware that anti-idiotypic antibodies directed against antibodies according to the invention provide useful structural information concerning the identity and mechanism of action of the receptor site for the G protein.

While the invention is described in detail with reference to human respiratory syncytial virus, it will be clearly understood that the invention is applicable to the genus *Pneumovirus* in general, and particularly to bovine RSV in addition to human RSV. It will be evident from the following description that while the sequence of the G protein of bovine RSV varies to some extent, there is significant conservation of a specific sequence, and that the cysteine residues are in the same position as in human RSV G protein. The conservation of the disulphide bond bonding pattern in all strains tested indicates that this pattern has not varied during evolution of the virus, and that it is functionally significant.

Brief Description of the Figures

Figure 1A is a diagrammatic representation of the RSV G protein predicted by gene sequence analysis. The clear area containing a single cysteine residue (I) is the cytoplasmic domain, the black region (II) is the transmembrane domain and subdomains shaded gray (III & V) are the putative heavily glycosylated regions of the

ectodomain separated by the non-glycosylated disulphide subdomain (IV);

Figure 1B shows the disulphide arrangement determined in this study to involve pairing of cysteine 173 with cysteine 186, and cysteine 176 with cysteine 182;

Figure 2 shows the amino acid sequence encompassing residues 149-197 of the G proteins of variants of different subtypes of RSV. Sequences 1-15 are human RSV strains, sequence 1 is that of the A2 strain of the A subtype (Satake et al, 1985; Wertz et al, 1985), sequence 2 is the Long A strain of the A subtype (Johnson et al, 1987), and sequences 3-8 are natural variants of the A subtype isolated in the same locality in a single year (Cane et al, 1991). Sequences 9-15 are natural variants of the B subtype isolated in different localities over a 29-year period (Johnson et al, 1987; Cane et al, 1991; Sullender et al, 1990; Sullender et al, 1991). Sequence 16 is that of Bovine RSV (Lerch et al, 1990). Sequences 17 and 18 are variants of human RSV, R10c/1 and R10c/10, which were generated by propagation of the Long A strain in the presence of a monoclonal antibody directed to the cysteine-containing constant region of the ectodomain of the G protein (Rueda et al, 1994);

Figure 3 illustrates the HPLC separation of protease fragments of RSV strain A2 G protein produced by tryptic digestion of the entire protein (A) and by digestion of the fraction eluting at approximately 73 minutes during HPLC of the tryptic digest with different proteases (B-D). Chromatograms B, C and D are of digests obtained using pepsin, thermolysin, and post-proline cleavage enzyme, respectively;

Figure 4 shows MALDI-TOF-MS spectra of components of the fraction eluting at approximately 73 minutes during HPLC of the tryptic digest of Figure 3A. A spectrum of an aliquot of the tryptic fraction is shown in A, and a spectrum of an aliquot of the unfractionated peptic digest

of this tryptic fraction is shown in B. The unfractionated peptic digestion was performed as for Figure 3, except that the temperature was 22°C. C and D represent spectra of fractions eluting at approximately 61 minutes and 64 minutes during HPLC of the peptic digest (Figure 3B). Spectrum B was recorded in the linear mode. Spectra A and B were recorded with matrix 3 and spectra C and D were recorded with matrix 4;

Figure 5 shows the proposed identities of peptide fragments detected by MALDI-TOF-MS in various digests and HPLC fractions. Theoretical m/z values corresponding to the proposed fragment identities are presented next to the corresponding sequence. All m/z values are for the oxidized sequences, except for fragments 1R, 2R and 3R, which are for reduced forms of these sequences;

Figure 6 illustrates MALDI-TOF-MS spectra obtained by reduction of fragments 3(A) and 2(B) of the peptic digest of tryptic fragment 1. Matrix 4 was used to record both spectra;

Figure 7 shows MALDI-TOF-MS spectra of an unfractionated thermolytic digest of tryptic fragment 1(A) and the thermolytic fragment eluting at approximately 54 minutes during HPLC of the thermolytic digest of Figure 3C (B). Conditions for thermolytic digestion were as described for Figure 3 except that 0.5 mM CaCl_2 was used. Matrix 4 was used to record both spectra;

Figure 8 shows MALDI-TOF-MS spectra of an unfractionated post-proline cleavage enzyme digest of tryptic digest 1 (A), the fraction eluting at approximately 63 minutes during HPLC (Figure 3D) of this digest (B) and an unfractionated post-proline cleavage enzyme digest of peptic fragment 2 (C). The unfractionated digests were prepared as for Figure 3, except that final enzyme concentrations of 0.1 mg/ml and 10 $\mu\text{g/ml}$ were used to obtain spectra A and C, respectively. Matrix 4 was used to record all spectra;

Figure 9 shows post-source decay fragment ion spectra of peptic fragment 2 (A), peptic fragment 3 (B) and post-proline cleavage enzyme fragment 5 (C). Fragment ions 1-7, inclusive, correspond to an N-terminal fragment ion series of the b-type resulting in fragmentation of the amino acid residues with or without the peptide, A I C K. Fragment ions 8-14, inclusive, correspond to a C-terminal fragment ion series of the y-type. This fragmentation pattern is presented in a diagrammatic form in Figure 10 together with m/z values for the numbered fragment ions of peptic fragment 2. An expanded portion of spectrum A (m/z = approximately 850 to 1650) is presented above the full spectrum. Matrix 3 was used to record spectra A and B and matrix 1 was used to record spectrum C; and

Figure 10 illustrates the proposed fragmentation pattern of peptic fragment 2 based on data from Figure 9A.

Detailed Description of the Invention

Inspection of the deduced amino acid sequence of the G protein of many RSV isolates (Satake et al, 1985; Wertz et al, 1985; Johnson et al, 1987; Cane et al, 1991; Sullender et al, 1990; Sullender et al, 1991; Garcia et al, 1994) reveals several structural domains, which are illustrated in Figure 1. The N-terminal region (residues 1-38) is located on the inner aspect of the viral envelope, and is relatively conserved, as is the transmembrane region (residues 39-66). However, the ectodomain (232 residues) has two regions of comparative variation bordering a central region (residues 149-197), which is conserved within subgroups and contains 4 closely positioned cysteine residues which are conserved in all RSV sequences. As shown in Figure 2, this region also has a sequence of 13 amino acids, including 2 of the conserved cysteine residues, which is identical in all wild type isolates of RSV that infect humans. The variable regions contain potential sites for N-linked glycosylation of

asparagine, and have an abundance of serine and threonine residues which are potential sites for O-linked oligosaccharides. Thus the ectodomain comprises 7 occurrences of the consensus tripeptide sequence
5 asparagine-Xaa-threonine/serine, the motif for asparagine-linked glycosylation, although at three of these sites Xaa is proline, which is a contraindication of such glycosylation. A relative abundance of proline residues in the regions high in serine and threonine suggests the
10 presence of O-linked oligosaccharides. Some functional studies indicate an active role for the O- and N-linked oligosaccharides of the RSV membrane proteins in cellular invasion (Lambert, 1988), but systematic analyses of the structures and positioning of the oligosaccharides remain
15 to be performed.

Experimental Procedures

Peptide Isolation

Strain A2 RSV G protein was isolated by immunoaffinity chromatography (Walsh, 1984), with
20 modifications to include immunoaffinity columns specific for RSV F and nucleocapsid proteins prior to a final G protein antibody column and elution from the affinity column with potassium thiocyanate. Lyophilized G protein samples were reconstituted in sufficient 0.1 M NH_4HCO_3 to
25 result in a final concentration of 0.01% Triton X-100 (v/v), 0.14 M NaCl and 10 mM phosphate buffer (pH 7.2 in the absence of NH_4HCO_3). N-ethylmaleimide was also added to a final concentration of 1 mM. Digestion of the intact protein was performed for 4 hours at 37°C using two
30 additions of 1% (w/w) of sequencing grade trypsin (Boehringer-Mannheim) with the second addition made at 2 hours. Subdigestion of peptide fragments isolated by high performance liquid chromatography (HPLC) was achieved with pepsin (Boehringer-Mannheim), thermolysin (Calbiochem)
35 and/or post-proline cleavage enzyme (Seikagaku Corporation,

Tokyo). Details of individual subdigestion protocols are described below in association with specific experiments.

Proteolytic fragments were isolated by reverse phase HPLC (RP-HPLC) using slight variations of a previously described protocol (Gorman et al, 1990), using a 2.1 mm x 25 cm column of octadecasilica (Vydac), a flow rate of 150 μ l/min and a linear gradient from 0.1% (v/v) aqueous trifluoroacetic acid to 80% (v/v) aqueous CH_3CN containing 0.09% (v/v) trifluoroacetic acid, developed over 90 minutes. Gradients were generated using a Hewlett Packard chromatography system comprising a 1090M solvent delivery system under the control of a DOS Chemstation, and elution of peptides was monitored at 214 nm using a 1090 diode array detector.

Mass Spectrometry

Matrix-assisted laser desorption/ionisation time of flight mass spectrometry (MALDI-TOF-MS) was performed using a Bruker Reflex mass spectrometer (Bruker-Franzen Analytik GmbH, Bremen, Germany). Samples were deposited on to target surfaces after mixing with an equal volume of the supernatant fraction of a saturated mixture of α -cyano-4-hydroxy-cinnamic acid (matrix 1) or 3,5-dimethoxy-4-hydroxy-cinnamic acid (matrix 2) in 33% (v/v) aqueous CH_3CN containing 0.1% (v/v) trifluoroacetic acid (Beavis et al, 1992), or a 10 mg/ml solution of α -cyano-4-hydroxy-cinnamic acid in 50% (v/v) $\text{C}_2\text{H}_5\text{OH}/\text{CH}_3\text{CN}$ (matrix 3), or a 10 mg/ml solution of 2,6-dihydroxyacetophenone in 50% (v/v) $\text{C}_2\text{H}_5\text{OH}/\text{CH}_3\text{CN}$ containing 0.1 M di-ammonium hydrogen citrate (matrix 4) (Gorman et al, 1996). Ionization was achieved using a nitrogen laser pulsed at a repetition rate of 3 Hz. Laser irradiance was adjusted to threshold levels in order to observe intact molecular ions, which were accelerated to a potential of 28.5 kV on to a hybrid microchannel plate-photomultiplier linear detector or subsequently reflected with a reflectron potential of 30 kV on to a dual

microchannel plate detector. Except where specifically noted, molecular ion masses were determined in the reflectron mode. Matrix ions were deflected by application of a 2 kV potential across deflector plates placed
5 immediately after the ion acceleration region in order to avoid saturation of the detectors. All measurements were made at a digitization rate of 250 Mhz. Masses were assigned to intact peptide ions by reference to an external calibration file created using the flight times of the
10 components of a mixture of 200 fmoles of angiotensin II ($MH^+ = 1046.56$; monoisotopic mass), 400 fmoles of adrenocorticotrophic hormone residues 18-39 ($MH^+ = 2466.73$; average mass) and 2 pmoles of bovine insulin ($MH^+ = 5734.54$; average mass) applied to a separate target
15 spot.

Analysis of metastable ions arising from post-source decay was performed using 25% stepwise decrements in the reflectron potential and increasing the laser irradiance to optimise production of ions in each voltage
20 window (Spengler et al, 1992; Kaufmann et al, 1993; Kaufmann et al, 1994). Masses were assigned to metastable ions by reference to a calibration table created by determining the behaviour of metastable ions of known mass, produced from adrenocorticotrophic hormone residues 18-39 ,
25 at various reflectron potentials (Rouse et al, 1995). As described above, data were acquired at a digitization rate of 250 MHz. Assembly of the individual spectra for each reflection voltage on to a continuous mass scale was performed using Bruker FAST software routines within the
30 Bruker XMASS software package.

Reduction of Disulphide Bonds

Disulphide containing peptides were reduced, after adjusting HPLC fractions to pH 5 by the addition of 1 M aqueous di-ammonium hydrogen citrate to a final
35 concentration of 0.1 M, by addition of 50 mM aqueous

tris(2-carboxyethyl)-phosphine (Molecular Probes) to a final concentration of 5 mM and incubating the mixtures at 65°C for 20 minutes. Reduced samples were mixed with an equal volume of 2,6-dihydroxyacetophenone in 50% (v/v) C₂H₅OH/CH₃CN and applied to a sample target for mass spectrometric analysis.

Edman Degradation

Stepwise amino acid sequence analysis of peptides was performed by automated Edman degradation using a Hewlett Packard G1000A solid-phase protein sequenator.

Example 1 Disulphide Determination by Analysis of Proteolytic Fragments

The whole G protein was digested with trypsin, and a fraction of the tryptic digest was then subjected to further digestion with pepsin, thermolysin, or post-proline cleavage enzyme as described. The digests were analysed by RP-HPLC, and the results are summarized in Figure 3.

Chromatogram A resulted from injection of 100 µl of a digest which contained approximately 40 µg of G protein exposed to trypsin for 4 hours at 37°C (see experimental procedures for detailed conditions). Subdigestions of the fraction eluting at 73 minutes in chromatogram A were achieved after removal of the CH₃CN using a stream of high purity nitrogen. Pepsin (10 µl of a 1 mg/ml solution in 5% (v/v) formic acid) was added to 100 µl of the fraction and digestion was allowed to proceed for 2 h at 37°C prior to injecting 100 µl of the digest to generate chromatogram B. The fraction was prepared for thermolytic digestion by mixing 45 µl of the fraction with 45 µl of 0.1 M NH₄HCO₃ and 11 µl of 0.01 M CaCl₂. Thermolysin (10 µl of a 1 mg/ml solution in 0.1 M NH₄HCO₃) was added and digestion allowed to proceed for 2 hours at 37°C prior to injecting 100 µl to generate chromatogram C. The fraction was prepared for post-proline cleavage enzyme

digestion by mixing 45 µl of the fraction with 20 µl of 0.1 M NH_4HCO_3 before adding 45 µl of 0.1 mg/ml solution of the enzyme in the enzyme in 0.1 M ammonium acetate to give a final pH of 6.5. Digestion was allowed to proceed for 2 hours at 37°C prior to injecting 100 µl of the digest to generate chromatogram D.

The following fragments were produced by enzymatic digestion:

Fragment 1	Trypsin cleavage of G protein;
Fragments 2 & 3	Pepsin cleavage of Fragment 1;
Fragment 4	Thermolysin cleavage of Fragment 1;
Fragment 5	Cleavage of Fragment 1 with post-proline protease;
Fragment 6	Cleavage of Fragment 2 with post-proline protease;
Fragment 2R	Reduced Fragment 2; and
Fragment 3R	Reduced Fragment 3.

Cleavage with Trypsin

RP-HPLC of tryptic digests of the G protein consistently revealed only a few discrete peaks of absorbance at 214 nm at the column breakthrough and at approximately 10.5, 25 and 73 minutes (Figure 3A). The remainder of the chromatogram consisted of several series of broad baseline rises consisting of poorly resolved peaks of absorbance at 214 nm. This appearance is consistent with extensive attachment of heterogenous oligosaccharides to most of the peptide constituents of the digest. The peak eluting at 10.5 minutes represented N-ethylmaleimide, which was added to the digest as a precaution against disulphide bond interchange or disulphide bond oxidation of cysteine-containing fragments. The peak eluting at 10.5 minutes was not present in a digest from which N-ethylmaleimide was omitted.

The other early-eluting discrete peaks failed to produce data when examined by MALDI-TOF-MS; however, as shown in Figure 4A, the peak at 73 minutes produced intense ion signals at m/z values of 4108.0 and 4125.3. These masses are consistent with the tryptic peptide spanning residues 152 to 187 of the G protein (Fragment 1), taking into account oxidation of the four cysteines of this sequence to cystine residues, which leads to a loss of 4 Da in mass from both peptides. Partial conversion of the N-terminal glutamine residue 152 to pyroglutamic acid apparently accounts for the difference of 17 Da in mass between these ions. These data also indicate that Fragment 1 does not have any carbohydrate attached to the asparagine residue at position 179, the threonine residue at position 181, or the serine residues at positions 157, 174 and 177.

Subcleavage with Pepsin

Cleavage of isolated Fragment 1 with pepsin and analysis of the unfractionated digest of MALDI-TOF-MS produced ions consistent with residues 152 to 164 and residues 169 to 187 (Figure 4B). Ions at $m/z = 1653.2$ and $m/z = 1670.0$, representing residues 152 to 165, were spaced by 17 Da, indicating a mixture of glutaminyl and pyroglutamyl residues derived from the N-terminus of the original tryptic Fragment 1. Ions at 2096.7 and 2115.7 represented the C-terminal portion of Fragment 1 (residues 169 to 187), allowing for peptide bond cleavage within a cystine loop of the heavier peptide (Fragments 2 and 3). As for the parent tryptic peptide, 4 Da had to be subtracted from the theoretical masses of the C-terminal portions to obtain correspondence with the experimentally observed masses. This provided further evidence that the four cysteine residues of the sequence were in disulphide linkage.

Fragments 2 and 3 were isolated by RP-HPLC (Figure 3B) and analysed as isolated fragments which provide corroboration of the identities assigned to ions in the unfractionated digest, especially the spacing of 18 Da of ions representing the C-terminus of tryptic Fragment 1, which indicated intra-disulphide loop peptide bond cleavage for the heavier ion. Peaks at 52 and 52.5 minutes corresponded to N-terminal peptic fragments, the peak of 61 minutes corresponded to the heavier of the C-terminal peptic fragments (Fragment 2; Figure 4C), and the peak at 64 minutes corresponded to the lighter of the C-terminal fragments (Fragment 3; Figure 4D). Mass analysis of these peptides after chemical reduction showed an increase in mass of 4 Da for the lighter of the C-terminal fragments, consistent with acquisition of four protons as a consequence of reduction of two disulphide bonds (Figure 6A). The heavier of the unreduced peptides actually lost mass, corresponding to loss of the sequence Ala-Ile-Cys-Lys and gain of 3 protons following reduction of two disulphide bonds (Figure 6B). These data indicate that the peptic cleavage within a disulphide loop to produce the heavier of the C-terminal peptic fragments (Fragment 2) occurred after the sole tryptophan of the parent tryptic Fragment 1 (tryptophan 183 of the G protein).

Subcleavage with Thermolysin

Cleavage of the tryptic Fragment 1 with thermolysin and direct analysis of the digest reaction by MALDI-TOF-MS produced ions consistent with cleavages prior to phenylalanine residue 19 of Fragment 1 and prior to isoleucines at positions 24 and 34 of Fragment 1. Ions diagnostic of these cleavages were at m/z values of 912.9 and 1106.9 (Figure 7A). The ion at $m/z = 912.9$ is consistent with disulphide bridging between 173 and 186 (residues 19-23 of Fragment 1 linked to residues 34-36),

and the ion at $m/z = 1106.9$ is consistent with disulphide bridging between cysteines 176 and 182, but without cleavage of intra-cystine-loop peptide bonds. RP-HPLC of the thermolytic digest revealed a complex series of peaks, as shown in Figure 3C. Most of these peaks appeared to have been derived from the enzyme preparation, as they were present in a chromatogram produced using a mock digest which lacked Fragment 1. Some of these peaks produced ions which did not correspond to any portion of Fragment 1. The digest had one peak at approximately 38.5 minutes which yielded an ion at $m/z = 912.2$, consistent with the cysteine 173 to 186 loop. However, this fraction was a mixture of peptides, as evidenced by other ions at higher m/z values, and was not characterized any further. The fraction eluting at approximately 54 minutes was not present in the mock digest, and yielded the correct mass for the peptide containing the cysteine 176 to 182 loop (Fragment 4), as shown in Figure 7B. Automated Edman degradation sequencing produced an N-terminal sequence of Ile-Xaa-Ser-Asn, which is consistent with the identification of this fragment by mass analysis, with Xaa representing a gap corresponding to retention of the PTH derivative of one half cystine residue on the sequencer cartridge due to disulphide linkage to its half cystine pair.

Subcleavage with Post-Proline Cleavage Enzyme

Cleavage of tryptic Fragment 1 with a post-proline cleavage enzyme produced a fragment (Fragment 5) containing the two disulphides, but without intra-disulphide loop cleavage at the proline residue in the cysteine 176 to 182 loop. Ions with m/z values indicative of this fragment ($m/z = 1639.7$) were observed in both the digestion reaction mixture (Figure 8A) and in a fraction at approximately 63 minutes generated by HPLC of the reaction mixture (Figure 3D). This is shown in Figure 8B. Post-

proline cleavage of the heavier of the C-terminal peptic fragments of Fragment 1 (ie. Fragment 2) also achieved cleavage at the extra-cysteine loop proline but not the intra-loop proline (Fragment 6), as indicated by appearance
5 of an ion at $m/z = 1658.8$ in the digest illustrated in Figure 8C. We attempted to obtain further fragments consistent with the disulphide bond pattern indicated above, using cleavage strategies involving chymotrypsin, proteinase K and mild acid; however, these strategies
10 either failed to contribute additional data or were not rewarding at all.

The residues involved in each fragment, and their observed and theoretical m/z ratios, are summarized in Table 1, and the structure of each fragment, indicating its
15 disulphide bonds, is shown in Figure 5. It can be seen that the pattern of disulphide bonding is the same in each fragment, and that this pattern is destroyed by reduction.

Table 1
Enzymatically-Produced Fragments of the RSV G-Protein
Containing Ectodomain Cystine/Cysteine Residues

Fragment	Cleavage	Residues	Observed/m/z	Theoretical m/z
1	Trypsin cleavage of G protein	152 - 187	4125.3/4108.0	4124.7/4107.7 ^{1,2}
2	Pepsin cleavage of 1	169 - 187	2115.8	2115.5 ^{1,3}
3	Pepsin cleavage of 1	169 - 187	2097.9	2097.5 ¹
4	Thermolysin cleavage of 1	175 - 184	1106.9	1107.3 ¹
5	Post-Proline Protease cleavage of 1	173 - 187	1639.7	1639.9 ¹
6	Post-Proline Protease cleavage of 2	173 - 187	1658.8	1658.0 ^{1,3}
2R	Reduction of 2	169 - 183	1685.7	1685.9 ³
3R	Reduction of 3	169 - 187	2101.3	2101.5

- ¹ Calculated assuming that all four cysteine residues are involved in disulphide bonds
- ² The difference of 17 Da between these ions is accounted for by cyclization of the N-terminal glutamine residue to pyroglutamic acid.
- ³ Calculated based on the addition of 18 Da to unreduced fragments to account for cleavage at the C-terminal peptide bond of tryptophan 183 and loss of the disulphide-linked A I C K sequence upon reduction.

Example 2

Disulphide Determination by Mass
Spectrometric Based Sequence Analysis
of Fragments 2, 3 and 5

Analysis of products of gas-phase metastable
5 decomposition of ions of peptic Fragment 2 by MALDI-TOF-MS
produced a series of fragment ions illustrated in
Figure 9A, which were consistent with the disulphide
bonding pattern deduced by analysis of proteolytic
10 fragments (Figure 5). The series of fragment ions obtained
is represented both diagrammatically and in tabular form in
Figure 10. These fragment ions are of the b- and y-type
(Roepstorff and Fohlman, 1984) representing cleavages at
the peptide bonds along the peptide backbone. Fragment
15 ions 1 to 4 inclusive are a series of b-type ions which are
independent of possible disulphide bonding arrangements,
but fragment ions 5 to 7 inclusive are diagnostic of the
indicated disulphide linkage, due to the concomitant loss
of mass of the A I C K sequence together with
20 fragmentations at Cys173 or Ser174 or Ile175 of the larger
peptide chain. Furthermore, this diagnosis is supported by
the occurrence of fragment ions 8 to 11, which also bear
the mass of the A I C K sequence, and by the failure to
observe this mass accompanying fragment ions 12 to 14.

A comparable analysis of peptic Fragment 3
25 revealed the sequence specific b-type fragment ions 2, 3
and 4 seen for peptic Fragment 2, which are independent of
the disulphide bonding pattern which are shown in
Figure 9B. Fragment ions of Fragment 3 at m/z values of
1983.3, 1836.7 and 1735.6 are potentially equivalent to
30 y-type ions 8, 9 and 10 respectively of Fragment 2 when a
mass difference due to inclusion of an additional peptide
bond in Fragment 3 is taken into account. Other prominent
fragment ions of Fragment 3 were apparent at m/z values of
288.4, 648.9 and 719.1. Only the ions at m/z values of
35 648.9 and 719.1 were also seen with Fragment 2. The ion at
 $m/z = 648.9$ can be rationalised as a b-type ion resulting

from cleavage between Ser174 and Ile175 of the peptide, plus cleavage of the disulphide bond involving Cys173. The ions at m/z values of 288.4 and 719.1 cannot be easily accounted for. None of the fragment ions of Fragment 2 which were used to support the disulphide bonding arrangement were observed with Fragment 3. This supports the logic used in interpretation of the ion series of Fragment 2 used to define the disulphide pattern. This logic was dependent upon identifying ions as being combinations of metastable ion masses due to cleavage along the peptide backbone at the N-terminus of the Fragment 2 plus mass contributed by the disulphide-linked A I C K sequence. The A I C K sequence was also linked by a peptide bond to Trp183 in Fragment 3, which explains why it was not liberated together with metastable fragment ions from this peptic fragment.

As shown in Figure 9C, post-proline cleavage Fragment 5 failed to produce metastable fragment ions of comparable intensity to those produced by Fragments 2 and 3. These observations with Fragment 5 support the conclusions drawn from the data on Fragments 2 and 3. Fragment 5 does not have the N-terminal N F V P sequence, or the cleavage following Trp183 required to produce fragment ions equivalent to fragment ions 1 to 4 and 8 to 11 seen with Fragments 2 and 3.

As shown in Figure 10 and Table 2, the results of analysis of metastable ions produced by peptic Fragments 2 and 3 and post-proline cleavage Fragment 5 (Figure 9) were consistent with the pattern deduced by analysis of proteolytic fragments as shown in Figure 5.

Values in Table 2 for the observed fragment ions are an average of three separate determinations with peptic Fragment 2. Fragment ions 5-7 (b-type ions), inclusive, and 8-11 (y-type ions), inclusive, are diagnostic of the proposed disulphide pattern, because they account for the mass of the linked peptide, AICK, in addition to the mass

- 25 -

produced by the cleavage of amino acids as indicated.

Table 2

N-Terminal Fragments			C-Terminal Fragments		
	Observed	Predicted		Observed	Predicted
1	-	115.10	8	2001.2 \pm 0.8	2001.44
2	262.4 \pm 0.2	262.27	9	1854.3 \pm 1.1	1854.26
3	361.4 \pm 0.3	361.41	10	1755.2 \pm 1	1755.13
4	458.6 \pm 0.2	458.52	11	1658.9 \pm 1	1648.01
5	992.9 \pm 0.5	993.25	12	1123.1 \pm 0.3	1123.29
6	1080.6 \pm 0.2	1080.33	13	1036.4 \pm 0.6	1036.21
7	1193.5 \pm 0.6	1193.49	14	923.1 \pm 0.6	923.05

Example 3 Synthesis of Disulphide-Bonded peptide

A fully synthetic peptide of sequence corresponding to that of Peptide 1 in Figure 2 (SEQ ID NO: 1), ie. amino acids 149 to 197 inclusive of the G protein of RSV strain A2, was prepared using conventional solid-phase methods.

This peptide preferentially formed the same disulphide bonding pattern as that identified in the previous examples.

10 Discussion

We have now shown that the disulphide bonding pattern of the ectodomain of the unusual attachment protein or G protein of RSV involves a preferred stable configuration with Cys173 linked to Cys186, and Cys176 linked to Cys182. This was achieved by a combination of analysis of proteolytic fragments of the protein and further analysis of metastable ions produced from the proteolytic fragments during MALDI-TOF-MS. These findings represent a potent demonstration of the utility of MALDI-TOF-MS for the mass analysis and structural elucidation of peptides, with simultaneous characterization of post-translational modifications. The observation that the synthetic peptide corresponding to residues 149 to 197 formed the same disulphide bond arrangement as the viral protein strongly indicates that the preferred configuration is actually the sole configuration

It is apparent that the disulphide loop between Cys176 and Cys182 forms a restricted region of accessibility, since the proline residue in this loop was not vulnerable to post-proline cleavage enzyme under conditions where another proline residue preceding the disulphide loops was cleaved. In contrast the loop between Cys173 and Cys186 appears to be more accessible, since peptide bonds within this loop were cleaved by both pepsin and thermolysin.

Our results are surprising in view of the extremely high degree of post-translational glycosylation of the RSV G protein. The characteristics of the chromatogram obtained by HPLC of a tryptic digest of the G protein indicated extensive glycosylation of the ectodomain. However, it is evident that the region of the G protein ectodomain which we have defined does not carry any oligosaccharides. Furthermore, the 3 and 10 residues attached to the N- and C-terminal ends, respectively, of this region do not have the potential for glycosylation. This represents 49 of the 232 residues of the ectodomain, or approximately 20%, which are not glycosylated.

Thus it is apparent that the ectodomain of the G protein has a subdomain structure, in which two highly glycosylated subdomains of 83 and 101 amino acid residues are separated by a comparatively smaller non-glycosylated subdomain which has a highly defined disulphide bond arrangement. The occupancy status of the remaining potential glycosylation sites and the characteristics of the glycans are yet to be determined. Definition of the glycosylation of the subdomains is essential in order to assess the contribution of oligosaccharides to the mechanism of action and immunobiology of the G protein.

The region of the G protein ectodomain containing the disulphides and the peptide sequences immediately adjacent to the N- and C-terminal ends of this region appear to have functional significance for both receptor interactions and immunological reactivity of the G protein. A reassessment of earlier antigenic analyses in the light of our results has indicated an important role for the disulphides in maintaining the structural integrity of the protein. Studies with nested sets of synthetic peptides representing overlapping portions of the ectodomain have demonstrated that rabbit polyclonal antibodies and murine monoclonal antibodies to the G protein and human convalescent sera from natural infection all react in

common with a peptide containing three of the four
cysteines of the ectodomain (Norrby et al, 1987). The
rabbit antisera also reacted with a variety of peptides,
but the convalescent sera only reacted with two other
5 peptides, one of which overlapped the commonly reactive
peptide and another closely positioned peptide, while the
monoclonals only reacted with the commonly reactive
cysteine containing peptide. It is possible that a wider
spectrum of antibody reactivities with the G protein might
10 have been evident had the epitope scanning experiments
utilised glycosylated domains of the G protein.

Subsequent studies indicated that the cysteine
containing region formed a subgroup-specific antigenic
determinant, and that intact disulphide bonds were
15 important for this characteristic (Akerlind-Stopner et al,
1990). Further support for the immunological importance of
this region came from studies with escape mutants generated
using a neutralising monoclonal antibody (Rueda et al,
1994). These escape mutants had mutations at either Cys182
20 or Cys186 of their G proteins (Figure 2). The overall
effect of these changes was apparently sufficient to enable
the mutant viruses to escape neutralisation but to retain
functionally effective G proteins, as indicated by their
ability to compete with wild-type virus in infectivity
25 assays. Thus, it is possible that the mutant viruses had
subtle, but immunochemically significant, differences in
the surface chemistry of the cysteine regions of the
ectodomains of their G proteins, while retaining a
functionally competent structural fold. From our results
30 it is apparent that these mutants retained the ability to
form one of the two correct disulphides of the ectodomain,
that is either the Cys173 to Cys186 or the Cys176 to Cys182
linkage. The replacement of the cysteine residues by
arginine residues in both cases presumably compensated for
35 the loss of stability associated with loss of a disulphide
bond by replacement with a residue with the ability to form

a salt bridge.

The functional importance of the disulphide region is shown by studies using various polypeptides produced by recombinant routes or by chemical synthesis to immunize experimental animals against challenge with live RSV. A recombinant vaccinia virus expressing a polypeptide bridging the disulphide region (residues 1-230 of the G protein) has been shown to produce neutralising antibodies and to confer protection from challenge with live RSV, with a response equivalent to that elicited by a recombinant vaccinia virus expressing full length G protein. In contrast, a recombinant vaccinia virus expressing a polypeptide terminating at residue 180 (residues 1-180) failed to provide protection (Olmstead et al, 1989). Another recombinant vaccinia construct encompassing residues 124-203, also conferred protection (Simard et al, 1995). The importance the disulphide region is also illustrated by finding that a synthetic peptide containing three of the cysteine residues (residues 174-187), which conferred protection from challenge by live RSV despite the fact that only non-neutralising serum antibodies were produced (Trudel et al, 1991).

Nested sets of synthetic peptides have also been used to attempt to define the portion of the G protein which interacts with the cellular receptor for RSV (Feldman and Hendry, 1996); however, none of these peptides from the ectodomain blocked binding of the G protein to RSV-susceptible cells. It was postulated that the peptides may have lacked secondary or tertiary structural elements required for interaction with receptors. However, as with the immunological studies, the lack of oligosaccharides on these peptides appears to have been overlooked by previous workers. Furthermore, the disulphide bond status of these peptides does not appear to have been addressed. It is conceivable that the structural elements missing from the

synthetic peptides involve correct disulphide bond pairing or another element contained by such disulphide bonds.

Knowledge of the actual disulphide linkage pattern of G protein ectodomain facilitates experimental
5 assessment of the functional and immunological roles of the disulphides and neighbouring peptide sequences. Our results have enabled us to develop strategies for synthesis of peptides with the correct disulphide bridging to probe receptor binding and immunological interactions of this
10 portion of the G protein. Furthermore, we have demonstrated that synthetic strategies for this subdomain of the G protein did not need to consider glycosylation. Peptide by-products with the incorrect disulphide bonding arrangements are theoretically possible from synthetic
15 approaches; however, these can easily be identified by routine methods, and will serve as control peptides for assessment of the relevance of the particular disulphide pattern determined herein. In fact, no such peptide by-products were observed. Peptide products with residual
20 blocking groups were obtained, and can also be used as controls.

It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding,
25 various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.

References cited herein are listed on the
30 following pages, and are incorporated herein by this reference.

REFERENCES

1. Akerlind-Stopner, B., Utter, G., Mufson, M.A.,
Orvell, C., Lerner, R.A. and Norrby, E.
Journal of Virology, 1990 64 5143-5148
2. Alansari H. and Potgieter, N.D.
Virology, 1993 196 873-877
3. Beavis, R.C., Chaudhary, T. and Chait, B.T.
Organic Mass Spectrometry, 1992 27 156-158
4. Cane, P.A., Matthews, D.A. and Pringle, C.R.
Journal of General Virology, 1991 72 2091-2096
5. Cane P.A. and Pringle, C.R.
Seminars in Virology, 1995 6 371-378
6. Choreo and Goodman
Acc. Chem. Res., 1993 26 266-273
7. Collins, P.L.
The Paramyxoviruses. Kingsbury, D.W. ed New York:
Plenum Press; 1991 103-161
8. Dore-Duffy, P. and Howe, C.
Proc. Soc. Exper. Biol. Med., 1978 157 622-625
9. Feldman S.A. and Hendry, R.M.
Proceedings of the 13th Annual Meeting of the American
Society for Virology, 1996
10. Garcia, O., Martin, M., Dopazo, J., Arbiza, J.,
Erabasile, S., Russi, J., Hortal, M., Perez-Brena, P.,
Martinez, I., Garcia-Barreno, B. and Melero, J.A.
Journal of Virology, 1994 68 5448-5459

11. Gorman, J.J., Corino, G.L. and Shiell, B.J.
Biomed. Environ. Mass Spectrometry, 1992 27 156-158
12. Gorman, J.J., Ferguson, B.L. and Nguyen, T.N.
Rapid Communications in Mass Spectrometry, 1996 10 (5)
529-536
13. Gruber C. and Levine, S.
Journal of General Virology, 1983 64 825-832
14. Gruber C. and Levine, S.
Journal of General Virology, 1985 66 417-432
15. Hall, C.B.
Science, 1994 265 1393-1394
16. Heilman, C.A.
Journal of Infectious Diseases, 1990 161 402-406
17. Henderson, F.W., Collier, A.M., Clyde Jr, W.A. and
Denny, F.W.
New England Journal of Medicine, 1979 300 530
18. Johnson, P.R., Spriggs, M.K., Olmsted, R.A. and
Collins, P.L.
Proc. Natl. Acad. Sci. USA, 187 84 5625-5629
19. Kaufmann, R., Kirsch, D. and Spengler, B.
International Journal of Mass Spectrometry and Ion
Processes, 1994 131 355-385
20. Kaufmann, R., Spengler, B. and Lutzenkirchen, F.
Rapid Communications in Mass Spectrometry, 1993 7
902-910

21. Kingsbury, D.W.
Virology. Fields, B.N./ Knipe, D.M. ed New York:
Raven Press, 1990 945-962
22. Lambert, D.M.
Virology, 1988 164 458-466
23. Lambert D.M. and Pons, M.W.
Virology, 1983 130 204-214
24. Lerch, R.A., Anderson, K. and Wertz, G.W.
Journal of Virology, 1990 64 5559-5569
25. Levin, M.J.
Journal of Paediatrics, 1994 124 S22-S27
26. Levine, S.
Journal of Virology, 1977 21 427-431
27. McIntosh, K and Chanock, R.M.
in Virology: Fields, B.N. and Knipe, D.M. (eds) Raven
Press NY (1990)
28. Markwell, M.A.
The Paramyxoviruses. Kingsbury, D.W. ed New York:
Plenum Press; 1991 407-426
29. Morrison T. and Portner, A.
The Paramyxoviruses. Kingsbury, D.W. ed New York:
Plenum Press; 1991 347-382
30. Murray, J., Selleck, P., Hooper, P., Hyatt, A., Gould,
A., Gleeson, L., Westbury, H., Hiley, L., Selvey, L.,
Rodwell, B., and Ketterer, P.
Science, 1995 268 94-97

31. Norrby, E., Mufson, M.A., Alexander, H., Houghten, R.A. and Lerner, R.A.
Proc. Natl. Acad. Sci. USA, 1987 84 6572-6576
32. Olmstead, R.A., Murphy, B.R., Lawrence, L.A., Elango, N., Moss, B. and Collins, P.L.
Journal of Virology, 1989 63 (1) 411-420
33. Olson et al
J. Med. Chem., 1993 36 3039-3049
34. Roepstorff, P. and Fohlman, J.
Biomedical Mass Spectrometry, 1984 11 601
35. Rouse, J.C., Yu., W. and Martin S.A.
Journal of American Society for Mass Spectrometry, 1995 6 822-835
36. Rueda, P., Garcia-Barreno, B. and Molero, J.A.
Virology, 1994 198 653-662
37. Satake, M., Coligan, J.E., Elango, N., Norrby, E. and Venkatesan, S.
Nucleic Acids Research, 1985 21 7795-7812
38. Simard, C., Nadon, F., Seguin, C. and Trudel, M.
Antiviral Research, 1995 28 303-315
39. Spengler, B., Kirsch, D., Kaufmann, R. and Jaeger, E.
Rapid Communications in Mass Spectrometry, 1992 6 105-108
40. Sullender, W.M., Anderson, K. and Wertz, G.W.
Virology, 1990 178 195-203

41. Sullender, W.M. Mufson, M.A., Anderson, L.A. and Wertz, G.W.
Journal of Virology, 1991 65 5425-5434
42. Sullender, W.M. and Wertz, G.W.
The Paramyxoviruses. Kingsbury, D.W. ed. New York: Plenum Press, 1991 383-406
43. Trudel, M., Nadon, F., Seguin, C. and Binz, H.
Virology, 1991 185 749-757
44. Walsh
Journal of General Virology, 1984 65 761-767
45. Wertz, G.W., Collins, P.L., Huang, Y., Gruber, C., Levine, S. and Ball, L.A.
Proc. Natl. Acad. Sci. USA, 1985 82 4075-4079

BIOMOLECULAR RESEARCH INSTITUTE

5 June 1996





FIGURE 1

		150	160	170	180	190	195
1	KQRQNKPPSKPNNDHFHFVFP	CSICSNNP	TCWAI	CKRIPNKKPGKK	A2		
2	-----N-----				Long A		
3	-----				A 642		
4	-----H-----				A 6614		
5	-----N-----				A 6256		
6	-----N-----				A 6190		
7	-----N-----				A 5857		
8	-----				A 1734		
9	-S-SKN-K-KD-Y-----	G-QL-KS-	T-SN-K-		B 18537		
10	-S-SKN-K-KD-Y-----	G-QL-KS-	T-SN-K-		B 8/60		
11	-P-PKN-K-KD-Y-----	G-QL-KS-	T-SN-K-		B 1355		
12	-P-LKN-K-KD-Y-----	G-QL-KS-	T-SN-K-		B 15291*		
13	-P-LKN-K-KD-Y-----	G-QL-KS-	T-SSN-K-		B 10010*		
14	-P-LKN-K-KD-Y-----	G-QL-KS-	T-SN-K-		B 4843		
15	-S-SKN-K-KD-Y-----	G-QL-KS-	T-SN-K-		B 9320		
16	NPSGSI--ENHQDHNN-QTLPY--	T-EG-LA-LSL-HIETERA-SRA			Bovine		
17	-----P-----	T-----R-----			AR10c/1		
18	-----S-----	R-T-----			AR10c/10		

FIGURE 2

* Isolates from the same child with an interval of one year between isolations.

Isolates of the human A variants R10c/1 and R10c/10 were generated by propagation of the Long A strain in the presence of a monoclonal antibody directed at the cysteine containing constant region on the G protein.

4/14





FIGURE 3A

5/14



FIGURES 3B to 3D

6/14





FIGURE 4A

7/14



FIGURES 4B TO 4D

8/14

QNKPPSKPNNDHFHFEVFNFVPCSICSNNPTCWAICK
Fragment 1
4124.7 / 4107.7

QNKPPSKPNNDHFHFEVFNFVPCSICSNNPTCWAICK
Fragment 1R
4128.7 / 4111.7

NFVPCSICSNNPTCW AICK
Fragment 2
2115.49

NFVPCSICSNNPTCW
Fragment 2R
1685.95

NFVPCSICSNNPTCWAICK
Fragment 3
2097.47

NFVPCSICSNNPTCWAICK
Fragment 3R
2101.51

ICSNNPTCWA
Fragment 4
1107.26

CSICSNNPTCWAICK
Fragment 5
1639.94

CSICSNNPTCW AICK
Fragment 6
1658.0

FIGURE 5

9/14




FIGURE 6

10/14




FIGURE 7

11/14




FIGURE 8

12/14





FIGURE 9A

13/14



FIGURES 9B & 9C




FIGURE 10

THIS PAGE BLANK (USPTO)